Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.375 USD | -1.24% | -1.98% | -0.47% |
05-14 | Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating | MT |
05-13 | Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.47% | 461M | |
+26.02% | 49.18B | |
+0.70% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+12.88% | 26.09B | |
-21.90% | 18.71B | |
+9.27% | 13.26B | |
+31.06% | 12.32B | |
-0.34% | 11.99B |
- Stock Market
- Equities
- VYGR Stock
- News Voyager Therapeutics, Inc.
- Oppenheimer Initiates Coverage on Voyager Therapeutics With Outperform Rating, $14 Price Target